Gholizadeh N, et al. - In this prospective study involving 36 patients with biopsy-proven central gland prostate cancer, researchers assessed the effectiveness of in vivo 3D ¹H MR spectroscopic imaging (3D ¹H MRSI) with a semi-localized adiabatic selective refocusing (sLASER) sequence and gradient-modulated offset-independent adiabatic (GOIA) pulses for central gland prostate cancer detection. In addition, 4 risk models have been developed to distinguish between normal vs cancer, low vs high-risk cancer, low vs intermediate cancer, and intermediate vs high-risk voxels. Data reported that the normal vs cancer diagnostic model achieved the highest predictive performance with 96.2% accuracy, 95.8% sensitivity, and 93.1% specificity. The accuracy, sensitivity and specificity of models of low vs high-risk cancer and low vs intermediate-risk cancer were 82.5%, 89.2%, 70.2%, and 73.0%, 84.7%, 60.8%, respectively. The intermediate vs high-risk model of cancer yielded less than 55% accuracy, sensitivity, and specificity. Findings revealed that the GOIA-sLASER sequence with an external phased-array coil enables rapid evaluation of central gland prostate cancer. It was noted that the classification provides a promising tool for diagnosing normal vs cancer, low- vs high-risk cancer, and low- vs intermediate-risk cancer.